Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 722 entries
Sorted by: Best Match Show Resources per page
Intravenous immune globulin suppresses angiogenesis in mice and humans.

Signal transduction and targeted therapy

Yasuma R, Cicatiello V, Mizutani T, Tudisco L, Kim Y, Tarallo V, Bogdanovich S, Hirano Y, Kerur N, Li S, Yasuma T, Fowler BJ, Wright CB, Apicella I, Greco A, Brunetti A, Ambati BK, Helmers SB, Lundberg IE, Viklicky O, Leusen JH, Verbeek JS, Gelfand BD, Bastos-Carvalho A, De Falco S, Ambati J.
PMID: 26925256
Signal Transduct Target Ther. 2016;1. doi: 10.1038/sigtrans.2015.2. Epub 2016 Jan 28.

Human intravenous immune globulin (IVIg), a purified IgG fraction composed of ~ 60% IgG1 and obtained from the pooled plasma of thousands of donors, is clinically used for a wide range of diseases. The biological actions of IVIg are...

Cite
Yasuma R, Cicatiello V, Mizutani T, et al. Intravenous immune globulin suppresses angiogenesis in mice and humans. Signal Transduct Target Ther. 2016;1doi: 10.1038/sigtrans.2015.2.
Yasuma, R., Cicatiello, V., Mizutani, T., Tudisco, L., Kim, Y., Tarallo, V., Bogdanovich, S., Hirano, Y., Kerur, N., Li, S., Yasuma, T., Fowler, B. J., Wright, C. B., Apicella, I., Greco, A., Brunetti, A., Ambati, B. K., Helmers, S. B., Lundberg, I. E., Viklicky, O., Leusen, J. H., Verbeek, J. S., Gelfand, B. D., Bastos-Carvalho, A., De Falco, S., & Ambati, J. (2016). Intravenous immune globulin suppresses angiogenesis in mice and humans. Signal transduction and targeted therapy, 1. https://doi.org/10.1038/sigtrans.2015.2
Yasuma, Reo, et al. "Intravenous immune globulin suppresses angiogenesis in mice and humans." Signal transduction and targeted therapy vol. 1 (2016). doi: https://doi.org/10.1038/sigtrans.2015.2
Yasuma R, Cicatiello V, Mizutani T, Tudisco L, Kim Y, Tarallo V, Bogdanovich S, Hirano Y, Kerur N, Li S, Yasuma T, Fowler BJ, Wright CB, Apicella I, Greco A, Brunetti A, Ambati BK, Helmers SB, Lundberg IE, Viklicky O, Leusen JH, Verbeek JS, Gelfand BD, Bastos-Carvalho A, De Falco S, Ambati J. Intravenous immune globulin suppresses angiogenesis in mice and humans. Signal Transduct Target Ther. 2016;1. doi: 10.1038/sigtrans.2015.2. Epub 2016 Jan 28. PMID: 26925256; PMCID: PMC4768485.
Copy Download .nbib Format: NLM
ERRα regulates the growth of triple-negative breast cancer cells via S6K1-dependent mechanism.

Signal transduction and targeted therapy

Berman AY, Manna S, Schwartz NS, Katz YE, Sun Y, Behrmann CA, Yu JJ, Plas DR, Alayev A, Holz MK.
PMID: 28890840
Signal Transduct Target Ther. 2017;2. doi: 10.1038/sigtrans.2017.35. Epub 2017 Aug 25.

Estrogen-related receptor alpha (ERRα) is an orphan nuclear factor that is a master regulator of cellular energy metabolism. ERRα is overexpressed in a variety of tumors, including ovarian, prostate, colorectal, cervical and breast, and is associated with a more...

Cite
Berman AY, Manna S, Schwartz NS, et al. ERRα regulates the growth of triple-negative breast cancer cells via S6K1-dependent mechanism. Signal Transduct Target Ther. 2017;2doi: 10.1038/sigtrans.2017.35.
Berman, A. Y., Manna, S., Schwartz, N. S., Katz, Y. E., Sun, Y., Behrmann, C. A., Yu, J. J., Plas, D. R., Alayev, A., & Holz, M. K. (2017). ERRα regulates the growth of triple-negative breast cancer cells via S6K1-dependent mechanism. Signal transduction and targeted therapy, 2. https://doi.org/10.1038/sigtrans.2017.35
Berman, Adi Y, et al. "ERRα regulates the growth of triple-negative breast cancer cells via S6K1-dependent mechanism." Signal transduction and targeted therapy vol. 2 (2017). doi: https://doi.org/10.1038/sigtrans.2017.35
Berman AY, Manna S, Schwartz NS, Katz YE, Sun Y, Behrmann CA, Yu JJ, Plas DR, Alayev A, Holz MK. ERRα regulates the growth of triple-negative breast cancer cells via S6K1-dependent mechanism. Signal Transduct Target Ther. 2017;2. doi: 10.1038/sigtrans.2017.35. Epub 2017 Aug 25. PMID: 28890840; PMCID: PMC5589335.
Copy Download .nbib Format: NLM
The intracellular signalosome of PD-L1 in cancer cells.

Signal transduction and targeted therapy

Escors D, Gato-Cañas M, Zuazo M, Arasanz H, García-Granda MJ, Vera R, Kochan G.
PMID: 30275987
Signal Transduct Target Ther. 2018 Sep 28;3:26. doi: 10.1038/s41392-018-0022-9. eCollection 2018.

Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells accelerates tumor progression. PD-L1 possesses two main pro-oncogenic functions. First, PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by binding to the inhibitory receptor PD-1. Second, PD-L1...

Cite
Escors D, Gato-Cañas M, Zuazo M, et al. The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther. 2018;3:26doi: 10.1038/s41392-018-0022-9.
Escors, D., Gato-Cañas, M., Zuazo, M., Arasanz, H., García-Granda, M. J., Vera, R., & Kochan, G. (2018). The intracellular signalosome of PD-L1 in cancer cells. Signal transduction and targeted therapy, 326. https://doi.org/10.1038/s41392-018-0022-9
Escors, David, et al. "The intracellular signalosome of PD-L1 in cancer cells." Signal transduction and targeted therapy vol. 3 (2018): 26. doi: https://doi.org/10.1038/s41392-018-0022-9
Escors D, Gato-Cañas M, Zuazo M, Arasanz H, García-Granda MJ, Vera R, Kochan G. The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther. 2018 Sep 28;3:26. doi: 10.1038/s41392-018-0022-9. eCollection 2018. PMID: 30275987; PMCID: PMC6160488.
Copy Download .nbib Format: NLM
Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy.

Signal transduction and targeted therapy

Ballatori SE, Hinds PW.
PMID: 29263893
Signal Transduct Target Ther. 2016 Mar 25;1:16001. doi: 10.1038/sigtrans.2016.1. eCollection 2016.

Osteosarcoma (OS) is the most common primary bone cancer in children and adolescents, affecting ~560 young patients in the United States annually. The term OS describes a diverse array of subtypes with varying prognoses, but the majority of tumors...

Cite
Ballatori SE, Hinds PW. Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy. Signal Transduct Target Ther. 2016;1:16001doi: 10.1038/sigtrans.2016.1.
Ballatori, S. E., & Hinds, P. W. (2016). Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy. Signal transduction and targeted therapy, 116001. https://doi.org/10.1038/sigtrans.2016.1
Ballatori, Sarah E, and Hinds, Philip W. "Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy." Signal transduction and targeted therapy vol. 1 (2016): 16001. doi: https://doi.org/10.1038/sigtrans.2016.1
Ballatori SE, Hinds PW. Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy. Signal Transduct Target Ther. 2016 Mar 25;1:16001. doi: 10.1038/sigtrans.2016.1. eCollection 2016. PMID: 29263893; PMCID: PMC5657420.
Copy Download .nbib Format: NLM
TIFA suppresses hepatocellular carcinoma progression via MALT1-dependent and -independent signaling pathways.

Signal transduction and targeted therapy

Shen W, Du R, Li J, Luo X, Zhao S, Chang A, Zhou W, Gao R, Luo D, Wang J, Hao N, Liu Y, Chen Y, Luo Y, Sun P, Yang S, Luo N, Xiang R.
PMID: 29263897
Signal Transduct Target Ther. 2016 Jul 22;1:16013. doi: 10.1038/sigtrans.2016.13. eCollection 2016.

TIFA, also called T2BP, was first identified using yeast two-hybrid screening. Our previous work showed that TIFA suppresses hepatocellular carcinoma (HCC) progression via apoptosis and cell cycle arrest. However, the mechanism by which this TIFA suppression occurs remains unclear....

Cite
Shen W, Du R, Li J, et al. TIFA suppresses hepatocellular carcinoma progression via MALT1-dependent and -independent signaling pathways. Signal Transduct Target Ther. 2016;1:16013doi: 10.1038/sigtrans.2016.13.
Shen, W., Du, R., Li, J., Luo, X., Zhao, S., Chang, A., Zhou, W., Gao, R., Luo, D., Wang, J., Hao, N., Liu, Y., Chen, Y., Luo, Y., Sun, P., Yang, S., Luo, N., & Xiang, R. (2016). TIFA suppresses hepatocellular carcinoma progression via MALT1-dependent and -independent signaling pathways. Signal transduction and targeted therapy, 116013. https://doi.org/10.1038/sigtrans.2016.13
Shen, Wenzhi, et al. "TIFA suppresses hepatocellular carcinoma progression via MALT1-dependent and -independent signaling pathways." Signal transduction and targeted therapy vol. 1 (2016): 16013. doi: https://doi.org/10.1038/sigtrans.2016.13
Shen W, Du R, Li J, Luo X, Zhao S, Chang A, Zhou W, Gao R, Luo D, Wang J, Hao N, Liu Y, Chen Y, Luo Y, Sun P, Yang S, Luo N, Xiang R. TIFA suppresses hepatocellular carcinoma progression via MALT1-dependent and -independent signaling pathways. Signal Transduct Target Ther. 2016 Jul 22;1:16013. doi: 10.1038/sigtrans.2016.13. eCollection 2016. PMID: 29263897; PMCID: PMC5661659.
Copy Download .nbib Format: NLM
Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.

Signal transduction and targeted therapy

Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, Chen K, Lin H, Taub JW, Ge Y.
PMID: 29263915
Signal Transduct Target Ther. 2017 Apr 07;2:17012. doi: 10.1038/sigtrans.2017.12. eCollection 2017.

Acute myeloid leukemia (AML) is a serious disease. The 5-year survival rates remain frustratingly low (65% for children and 26% for adults). Resistance to frontline chemotherapy (usually cytarabine) often develops; therefore a new treatment modality is needed. Bcl-2 family...

Cite
Luedtke DA, Niu X, Pan Y, et al. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduct Target Ther. 2017;2:17012doi: 10.1038/sigtrans.2017.12.
Luedtke, D. A., Niu, X., Pan, Y., Zhao, J., Liu, S., Edwards, H., Chen, K., Lin, H., Taub, J. W., & Ge, Y. (2017). Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal transduction and targeted therapy, 217012. https://doi.org/10.1038/sigtrans.2017.12
Luedtke, Daniel A, et al. "Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells." Signal transduction and targeted therapy vol. 2 (2017): 17012. doi: https://doi.org/10.1038/sigtrans.2017.12
Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, Chen K, Lin H, Taub JW, Ge Y. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduct Target Ther. 2017 Apr 07;2:17012. doi: 10.1038/sigtrans.2017.12. eCollection 2017. PMID: 29263915; PMCID: PMC5661618.
Copy Download .nbib Format: NLM
Overexpression of CIP2A is associated with poor prognosis in multiple myeloma.

Signal transduction and targeted therapy

Liu X, Cao W, Qin S, Zhang T, Zheng J, Dong Y, Ming P, Cheng Q, Lu Z, Guo Y, Zhang B, Liu Y.
PMID: 29263916
Signal Transduct Target Ther. 2017 May 26;2:17013. doi: 10.1038/sigtrans.2017.13. eCollection 2017.

Cancerous inhibitor of protein phosphatase 2A (CIP2A), an endogenous protein phosphatase 2A (PP2A) inhibitor, has been identified as an oncoprotein in promoting cancer initiation and progression of several types of cancer. However, the expression and the role played by...

Cite
Liu X, Cao W, Qin S, et al. Overexpression of CIP2A is associated with poor prognosis in multiple myeloma. Signal Transduct Target Ther. 2017;2:17013doi: 10.1038/sigtrans.2017.13.
Liu, X., Cao, W., Qin, S., Zhang, T., Zheng, J., Dong, Y., Ming, P., Cheng, Q., Lu, Z., Guo, Y., Zhang, B., & Liu, Y. (2017). Overexpression of CIP2A is associated with poor prognosis in multiple myeloma. Signal transduction and targeted therapy, 217013. https://doi.org/10.1038/sigtrans.2017.13
Liu, Xuewen, et al. "Overexpression of CIP2A is associated with poor prognosis in multiple myeloma." Signal transduction and targeted therapy vol. 2 (2017): 17013. doi: https://doi.org/10.1038/sigtrans.2017.13
Liu X, Cao W, Qin S, Zhang T, Zheng J, Dong Y, Ming P, Cheng Q, Lu Z, Guo Y, Zhang B, Liu Y. Overexpression of CIP2A is associated with poor prognosis in multiple myeloma. Signal Transduct Target Ther. 2017 May 26;2:17013. doi: 10.1038/sigtrans.2017.13. eCollection 2017. PMID: 29263916; PMCID: PMC5661621.
Copy Download .nbib Format: NLM
Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials.

Signal transduction and targeted therapy

Zhang WY, Liu Y, Wang Y, Wang CM, Yang QM, Zhu HL, Han WD.
PMID: 29263931
Signal Transduct Target Ther. 2017 Oct 09;2:17054. doi: 10.1038/sigtrans.2017.54. eCollection 2017.

No abstract available.

Cite
Zhang WY, Liu Y, Wang Y, et al. Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials. Signal Transduct Target Ther. 2017;2:17054doi: 10.1038/sigtrans.2017.54.
Zhang, W. Y., Liu, Y., Wang, Y., Wang, C. M., Yang, Q. M., Zhu, H. L., & Han, W. D. (2017). Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials. Signal transduction and targeted therapy, 217054. https://doi.org/10.1038/sigtrans.2017.54
Zhang, Wen-Ying, et al. "Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials." Signal transduction and targeted therapy vol. 2 (2017): 17054. doi: https://doi.org/10.1038/sigtrans.2017.54
Zhang WY, Liu Y, Wang Y, Wang CM, Yang QM, Zhu HL, Han WD. Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials. Signal Transduct Target Ther. 2017 Oct 09;2:17054. doi: 10.1038/sigtrans.2017.54. eCollection 2017. PMID: 29263931; PMCID: PMC5661643.
Copy Download .nbib Format: NLM
The role of TLRs in cervical cancer with HPV infection: a review.

Signal transduction and targeted therapy

Yang X, Cheng Y, Li C.
PMID: 29263932
Signal Transduct Target Ther. 2017 Nov 03;2:17055. doi: 10.1038/sigtrans.2017.55. eCollection 2017.

The main cause of cervical cancer is persistent infection with high-risk human papilloma virus (HR-HPV), but not all human papilloma virus (HPV) infections lead to cervical cancer. The key factors that determine the outcome of HPV infection remain poorly...

Cite
Yang X, Cheng Y, Li C. The role of TLRs in cervical cancer with HPV infection: a review. Signal Transduct Target Ther. 2017;2:17055doi: 10.1038/sigtrans.2017.55.
Yang, X., Cheng, Y., & Li, C. (2017). The role of TLRs in cervical cancer with HPV infection: a review. Signal transduction and targeted therapy, 217055. https://doi.org/10.1038/sigtrans.2017.55
Yang, Xiao, et al. "The role of TLRs in cervical cancer with HPV infection: a review." Signal transduction and targeted therapy vol. 2 (2017): 17055. doi: https://doi.org/10.1038/sigtrans.2017.55
Yang X, Cheng Y, Li C. The role of TLRs in cervical cancer with HPV infection: a review. Signal Transduct Target Ther. 2017 Nov 03;2:17055. doi: 10.1038/sigtrans.2017.55. eCollection 2017. PMID: 29263932; PMCID: PMC5668671.
Copy Download .nbib Format: NLM
Inhibiting cancer cell hallmark features through nuclear export inhibition.

Signal transduction and targeted therapy

Sun Q, Chen X, Zhou Q, Burstein E, Yang S, Jia D.
PMID: 29263896
Signal Transduct Target Ther. 2016 Jul 01;1:16010. doi: 10.1038/sigtrans.2016.10. eCollection 2016.

Treating cancer through inhibition of nuclear export is one of the best examples of basic research translation into clinical application. Nuclear export factor chromosomal region maintenance 1 (CRM1; Xpo1 and exportin-1) controls cellular localization and function of numerous proteins...

Cite
Sun Q, Chen X, Zhou Q, et al. Inhibiting cancer cell hallmark features through nuclear export inhibition. Signal Transduct Target Ther. 2016;1:16010doi: 10.1038/sigtrans.2016.10.
Sun, Q., Chen, X., Zhou, Q., Burstein, E., Yang, S., & Jia, D. (2016). Inhibiting cancer cell hallmark features through nuclear export inhibition. Signal transduction and targeted therapy, 116010. https://doi.org/10.1038/sigtrans.2016.10
Sun, Qingxiang, et al. "Inhibiting cancer cell hallmark features through nuclear export inhibition." Signal transduction and targeted therapy vol. 1 (2016): 16010. doi: https://doi.org/10.1038/sigtrans.2016.10
Sun Q, Chen X, Zhou Q, Burstein E, Yang S, Jia D. Inhibiting cancer cell hallmark features through nuclear export inhibition. Signal Transduct Target Ther. 2016 Jul 01;1:16010. doi: 10.1038/sigtrans.2016.10. eCollection 2016. PMID: 29263896; PMCID: PMC5661660.
Copy Download .nbib Format: NLM
Butyrate induces apoptosis by activating PDC and inhibiting complex I through SIRT3 inactivation.

Signal transduction and targeted therapy

Xu S, Liu CX, Xu W, Huang L, Zhao JY, Zhao SM.
PMID: 29263907
Signal Transduct Target Ther. 2017 Feb 10;2:16035. doi: 10.1038/sigtrans.2016.35. eCollection 2017.

The underlying anticancer effects of butyrate, an end-product of the intestinal microbial fermentation of dietary fiber, remain elusive. Here, we report that butyrate promotes cancer cell apoptosis by acting as a SIRT3 inhibitor. Butyrate inhibits SIRT3 both in cultured...

Cite
Xu S, Liu CX, Xu W, et al. Butyrate induces apoptosis by activating PDC and inhibiting complex I through SIRT3 inactivation. Signal Transduct Target Ther. 2017;2:16035doi: 10.1038/sigtrans.2016.35.
Xu, S., Liu, C. X., Xu, W., Huang, L., Zhao, J. Y., & Zhao, S. M. (2017). Butyrate induces apoptosis by activating PDC and inhibiting complex I through SIRT3 inactivation. Signal transduction and targeted therapy, 216035. https://doi.org/10.1038/sigtrans.2016.35
Xu, Sha, et al. "Butyrate induces apoptosis by activating PDC and inhibiting complex I through SIRT3 inactivation." Signal transduction and targeted therapy vol. 2 (2017): 16035. doi: https://doi.org/10.1038/sigtrans.2016.35
Xu S, Liu CX, Xu W, Huang L, Zhao JY, Zhao SM. Butyrate induces apoptosis by activating PDC and inhibiting complex I through SIRT3 inactivation. Signal Transduct Target Ther. 2017 Feb 10;2:16035. doi: 10.1038/sigtrans.2016.35. eCollection 2017. PMID: 29263907; PMCID: PMC5661613.
Copy Download .nbib Format: NLM
Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer.

Signal transduction and targeted therapy

Zhang H, Wang Y, Wu Y, Jiang X, Tao Y, Yao Y, Peng Y, Chen X, Fu Y, Yu L, Wang R, Lai Q, Lai W, Li W, Kang Y, Yi S, Lu Y, Gou L, Wu M, Yang J.
PMID: 29263918
Signal Transduct Target Ther. 2017 May 19;2:17015. doi: 10.1038/sigtrans.2017.15. eCollection 2017.

Antibody-drug conjugates (ADCs) take the advantage of monoclonal antibodies to selectively deliver highly potent cytotoxic drugs to tumor cells, which have become a powerful measure for cancer treatment in recent years. To develop a more effective therapy for human...

Cite
Zhang H, Wang Y, Wu Y, et al. Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer. Signal Transduct Target Ther. 2017;2:17015doi: 10.1038/sigtrans.2017.15.
Zhang, H., Wang, Y., Wu, Y., Jiang, X., Tao, Y., Yao, Y., Peng, Y., Chen, X., Fu, Y., Yu, L., Wang, R., Lai, Q., Lai, W., Li, W., Kang, Y., Yi, S., Lu, Y., Gou, L., Wu, M., & Yang, J. (2017). Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer. Signal transduction and targeted therapy, 217015. https://doi.org/10.1038/sigtrans.2017.15
Zhang, Hang, et al. "Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer." Signal transduction and targeted therapy vol. 2 (2017): 17015. doi: https://doi.org/10.1038/sigtrans.2017.15
Zhang H, Wang Y, Wu Y, Jiang X, Tao Y, Yao Y, Peng Y, Chen X, Fu Y, Yu L, Wang R, Lai Q, Lai W, Li W, Kang Y, Yi S, Lu Y, Gou L, Wu M, Yang J. Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer. Signal Transduct Target Ther. 2017 May 19;2:17015. doi: 10.1038/sigtrans.2017.15. eCollection 2017. PMID: 29263918; PMCID: PMC5661626.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 722 entries